Genmab — Maj 2025
-
Dose Selection for DuoBody
-CD40x4-1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.3677 -
Vi får en ordentlig en på hatten lige nu. Lad os se hvad der sker i løbet af dagen. Sidste gang han forsøgte noget lignende blev han jo stoppet af domstolene.
-
-
Aktiemarkedet er og bliver en nervøs k*lling og Genmab har altid været en volatil aktie. Det vil altid være ens egen mavefornemmelse, erfaring men fremfor alt ens egen personlige investeringsstrategi man altid skal holde for øje uanset hvordan markedet reagerer her og nu.
-
Derfor er medicinpriserne høje i USA https://proinvestor.com/boards/126327
-
hexabody-cd38 trial ended up only enrolling 130 of the expected 252 patients -so at least costs are a bit lower as expected... https://clinicaltrials.gov/study/NCT04824794?tab=history&a=25&b=26&compareMode=sideBySide#version-content-panel
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind